Clinical trial
Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression…
NCT00299221 · Newark Beth Israel Medical Center, Other · Completed
Key facts
| NCT number | NCT00299221 |
|---|---|
| Title | Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients |
| Official title | Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients |
| Acronym | TICTAC |
| Lead sponsor | Newark Beth Israel Medical Center, Other |
| Collaborators | Astellas Pharma Inc Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Immunosuppression |
| Intervention type | Drug |
| Interventions | Tacrolimus, combination therapy |
| Enrollment | 150 |
| Start date | Apr 1, 2004 |
| Primary completion | Jun 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Mar 6, 2006 |
| Last update posted | May 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: